AETHLON MEDICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.36 USD | -9.51% |
|
-6.85% | -37.90% |
| Feb. 14 | Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| Feb. 14 | Transcript : Aethlon Medical, Inc., Q3 2024 Earnings Call, Feb 14, 2024 |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18.01 | 14.23 | 24.61 | 22.5 | 8.786 | 3.564 | - |
| Enterprise Value (EV) 1 | 18.01 | 14.23 | 24.61 | 22.5 | 8.786 | 3.564 | 3.564 |
| P/E ratio | -2.79 x | -0.81 x | -3.12 x | -2.06 x | -0.65 x | -0.26 x | -0.39 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 78.4 x | 21.9 x | 37.3 x | 76.5 x | 15.3 x | - | - |
| EV / Revenue | 78.4 x | 21.9 x | 37.3 x | 76.5 x | 15.3 x | - | - |
| EV / EBITDA | - | - | -3,480,735 x | - | - | - | - |
| EV / FCF | - | - | -3,606,065 x | - | - | - | - |
| FCF Yield | - | - | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 126 | 936 | 1,212 | 1,541 | 2,297 | 2,620 | - |
| Reference price 2 | 142.5 | 15.20 | 20.30 | 14.60 | 3.825 | 1.360 | 1.360 |
| Announcement Date | 7/1/19 | 6/25/20 | 6/24/21 | 6/28/22 | 6/28/23 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.2296 | 0.6502 | 0.6591 | 0.2942 | 0.5742 | - | - |
| EBITDA | - | - | -7.071 | - | - | - | - |
| EBIT 1 | -5.999 | - | -7.89 | -10.42 | -11.9 | -13.43 | -13.71 |
| Operating Margin | -2,612.47% | - | -1,197.07% | -3,542.47% | -2,072.03% | - | - |
| Earnings before Tax (EBT) 1 | -6.195 | -6.38 | -7.892 | -10.42 | -12.03 | -13.5 | -14.53 |
| Net income 1 | -6.195 | -6.374 | -7.887 | -10.42 | -12.03 | -12.91 | -13.45 |
| Net margin | -2,697.7% | -980.32% | -1,196.59% | -3,540.84% | -2,094.87% | - | - |
| EPS 2 | -51.00 | -18.70 | -6.500 | -7.100 | -5.900 | -5.220 | -3.510 |
| Free Cash Flow | - | - | -6.825 | - | - | - | - |
| FCF margin | - | - | -1,035.48% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 7/1/19 | 6/25/20 | 6/24/21 | 6/28/22 | 6/28/23 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.132 | 0.0171 | 0.0131 | - | - | - | 0.5742 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.009 | -2.528 | -3.786 | -2.906 | -3.665 | -2.85 | -2.478 | -3.408 | -3.175 | -3.567 | -3.259 | -2.9 | -2.9 | -3 | -3 |
| Operating Margin | -1,522.16% | -14,766.06% | -28,854.42% | - | - | - | -431.5% | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.009 | -2.528 | -3.786 | -2.906 | -3.807 | -2.85 | -2.467 | -3.282 | -3.034 | -3.466 | -3.7 | - | - | - | - |
| Net income 1 | -2.008 | -2.526 | -3.785 | -2.906 | -3.807 | -2.85 | -2.467 | -3.282 | -3.034 | -3.466 | -3.218 | -2.777 | -2.777 | -2.877 | -2.877 |
| Net margin | -1,521.54% | -14,753.1% | -28,849.7% | - | - | - | -429.59% | - | - | - | - | - | - | - | - |
| EPS 2 | -1.300 | -1.600 | -2.500 | -1.900 | -1.800 | -1.200 | -1.100 | -1.400 | -1.220 | -1.370 | -1.230 | -1.090 | -1.080 | -1.120 | -1.110 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/14/22 | 6/28/22 | 8/9/22 | 11/14/22 | 2/13/23 | 6/28/23 | 8/10/23 | 11/14/23 | 2/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | -6.82 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | 0.06 | - | - | - | - |
| Capex / Sales | - | - | 9.09% | - | - | - | - |
| Announcement Date | 7/1/19 | 6/25/20 | 6/24/21 | 6/28/22 | 6/28/23 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.36
USD
Average target price
25.05
USD
Spread / Average Target
+1,741.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.90% | 3.56M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- AEMD Stock
- Financials Aethlon Medical, Inc.
